KAMADA LTD

KMDA14 Dec 2024
Healthcare
$5.84
+0.01 (+1.38%)
Lowest Today
$5.75
Highest Today
$5.88
Today’s Open
$5.84
Prev. Close
$5.79
52 Week High
$6.53
52 Week Low
$4.74
To Invest in KAMADA LTD

KAMADA LTD

Healthcare
KMDA14 Dec 2024
+0.01 (+1.38%)
1M
3M
6M
1Y
5Y
Low
$5.75
Day’s Range
High
$5.88
5.75
52 Week Low
$4.74
52-Week Range
52 Week High
$6.53
4.74
1 Day
-
1 Week
-7.08%
1 month return
-2.53%
3 month return
+9.28%
6 month return
+13.58%
1 Year return
-1.87%
3 Years return
-13.49%
5 Years return
-15.76%
10 Years return
-
Institutional Holdings
Vanguard Total Intl Stock Index Inv
1.04
Vanguard Developed Markets Index Admiral
0.54
Vanguard Instl Ttl Intl Stk Mkt Idx TrII
0.48
DFA International Small Company I
0.3
Forest Sea Eagle IL
0.3
MORE Israel Equities IL
0.29
Forest 80/20 IL
0.28

Market Status

Fundamentals
Market Cap
347.3 mln
PB Ratio
1.37
PE Ratio
22.27
Enterprise Value
286.46 mln
Total Assets
354.91 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Organisation
KAMADA LTD
Employees
378
Industry
Drug Manufacturers - Specialty & Generic
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step